Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258682 | 0.97 | CES2 (0.38) | CES2CES1CA9CA3CA6 | |
| SCHEMBL29716720 | 0.97 | CES2 (0.38) | CES2CES1CA9CA3CA6 | |
| SCHEMBL29919382 | 0.94 | CES2 (0.36) | CES2CES1CA9CA3CA6 | |
| SCHEMBL8986519 | 0.89 | CES2 (0.33) | CES2CES1CA9CA3CA6 | |
| Chloroform SCHEMBL9256697 | 0.87 | ADRA2A (0.34) | CES2CES1CA9CA3CA6 | |
| SCHEMBL516276 | 0.81 | CA9 (0.37) | CES2CES1CA9CA3CA6 | |
| Trifluoroacetic Acid SCHEMBL7263980 | 0.79 | CES1 (0.37) | CES2CES1CA9CA3CA6 | |
| SCHEMBL5509678 | 0.79 | CES2 (0.38) | CES2CES1CA9CA3CA6 | |
| SCHEMBL29061953 | 0.77 | CA1 (0.41) | CES2CES1CA1CA2CA4 | |
| SCHEMBL515819 | 0.77 | CES2 (0.36) | CES2CES1CA9CA3CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11890382-B2 | Edible plant-derived microvesicle compositions for diagnosis and treatment of disease | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230176038-A1 | Methods for Identifying Modulators of Insect Transient Receptor Potential Channels | BASF CORP (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230149316-A1 | EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISEASE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2021133566-A1 | METHODS FOR IDENTIFYING MODULATORS OF INSECT TRANSIENT RECEPTOR POTENTIAL CHANNELS | BASF CORPORATION (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-3311172-B1 | METHODS FOR IDENTIFYING COMPOUNDS THAT DIRECTLY BIND TO INSECT TRANSIENT RECEPTOR POTENTIAL CHANNELS | BASF SE (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3087391-B1 | METHODS FOR DETERMINING MODULATORS OF INSECT TRANSIENT RECEPTOR POTENTIAL V (TRPV) CHANNEL | BASF SE (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3735982-A1 | TARGETING GDF6 AND BMP SIGNALING FOR ANTI-MELANOMA THERAPY | The University of Massachusetts (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200246438-A1 | TARGETING GDF6 AND BMP SIGNALING FOR ANTI-MELANOMA THERAPY | UNIV MASSACHUSETTS (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200188311-A1 | EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISEASE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| EP-3268025-B1 | TARGETING GDF6 AND BMP SIGNALING FOR ANTI-MELANOMA THERAPY | UNIV MASSACHUSETTS (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2003004604-A9 | PHAGE DISPLAYED PDZ DOMAIN LIGANDS | GENENTECH INC (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004003554-A1 | A METHOD FOR THE DETECTION OF APOPTOSIS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20030235611-A1 | Direct cellular energy delivery system | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-25 | — | — | US | disclosed |
| WO-2003096973-A2 | A DIRECT CELLULAR ENERGY DELIVERY SYSTEM | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003097792-A2 | POLYPEPTIDE IMMOBILIZATION | THE UNIVERSITY OF CHICAGO (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003086174-A2 | A NEW METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF MALIGNANT DISEASES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030194754-A1 | Method for the diagnosis and prognosis of malignant diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-16 | — | — | US | disclosed |
| US-20030148264-A1 | Phage displayed PDZ domain ligands | GENENTECH, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030119054-A1 | Polypeptide immobilization | NATIONAL SCIENCE FOUNDATION | 2003-06-26 | — | — | US | disclosed |
| WO-2003004604-A2 | PHAGE DISPLAYED PDZ DOMAIN LIGANDS | GENENTECH, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148264-A1 | Phage displayed PDZ domain ligands | PDLIM5, CD2BP2, GOPC | CES2 4476/4885CES1 3678/4885CA9 4502/4885 |
| US-20030119054-A1 | Polypeptide immobilization | SURF4, QPCTL, QPCT | CES2 2830/4885CES1 2109/4885CA9 4747/4885 |
| US-20030235611-A1 | Direct cellular energy delivery system | NSF, MTREX, SLC25A6 | CES2 1696/4885CES1 1149/4885CA9 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.